Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.

You may also be interested in...



Lilly chooses another Corcept compound to combat Zyprexa weight gain

Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor

Lilly chooses another Corcept compound to combat Zyprexa weight gain

Lilly will fund studies to test effectiveness of Corcept Therapeutics' cortisol receptor antagonist CORT-108297 in rat models of olanzapine-induced weight gain, Corcept says Sept. 3. Corlux (mifepristone), Corcept's antipsychotic cortisol receptor antagonist also funded in part by Lilly, has reduced and mitigated weight gain associated with olanzapine (Lilly's atypical antipsychotic Zyprexa), but is more commonly known for its anti-progestational abortifacient properties (1Pharmaceutical Approvals Monthly September 2004, p. 14). CORT-108297 does not have Corlux's potent affinity for the PR receptor

Corlux Second Phase III Trial Enrolled For Psychotic Major Depression

Data from three Phase III trials of Corcept's Corlux for psychotic major depression will be available by year-end, the firm said

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel